Patients presenting with myocardial infarction (MI) in the absence of obstructive coronary artery disease (CAD) is termed MI with nonobstructive coronary arteries (MINOCA). The underlying pathophysiology of MINOCA is multifactorial and in situ formation and subsequent spontaneous lysis of a coronary thrombus is often hypothesized as one of the mechanisms. The objective of this study is to determine whether MINOCA patients had a greater prothrombotic tendency in comparison to MI patients with obstructive CAD (MICAD). Prospectively, blood samples of 25 consecutive MINOCA patients (58 (interquartile range [IQR]: 48, 75) years, 48% women) and 25 age-/gender-matched MICAD patients (58 (IQR: 50, 66) years, 48% women) were obtained at 1 month after the initial presentation and overall thrombin generation potential and congenital/acquired thrombophilia states were assessed. As regard to results, overall thrombin generation parameters were similar (p > 0.05) between the MINOCA and MICAD groups, highlighting similar endogenous thrombin potential (1,590 nM/min; IQR: 1,380, 2,000 vs. 1,750 nM/min; IQR: 1,500, 2,040, respectively). There were no significant differences between MINOCA and MICAD, respectively, in respect to the numbers of patients with congenital thrombophilia states including factor V Leiden (0 vs. 4%) and prothrombin gene mutation (8 vs. 4%), decreased antithrombin (8 vs. 0%), protein C (0 vs. 0%), and protein S (4 vs. 0%). None of the patients demonstrated presence of lupus anticoagulant and anticardiolipin antibodies. Although MINOCA patients revealed thrombotic characteristics that are similar to those with MICAD, the results from this study are inconclusive and a larger study with healthy control subjects is required to assess the risk of thrombosis in MINOCA.
Introduction
Myocardial infarction (MI) with nonobstructive coronary arteries (MINOCA) is considered as a "working diagnosis" for patients presenting with a suspected myocardial infarct in the absence of obstructive coronary artery disease (CAD) on angiography. 1 The recent European Society of Cardiology (ESC) acute MI guidelines included MINOCA and highlighted it is imperative that the underlying cause is identified for each patient since this will influence subsequent therapy. 2 Multiple mechanisms have been proposed and one postulated mechanism for MINOCA is in situ thrombus formation with subsequent lysis, thereby resulting in a morphologically normal angiogram 3 but with the underlying causative prothrombotic state potentially predisposing to a further event. A recent systematic review has reported that as many as 14% of patients with MINOCA may have an abnormality detected on thrombophilia screening. 27 Congenital thrombophilia disorders detected in patients with MINOCA include factor V Leiden (FVL), prothrombin gene mutation (PGM), and proteins C and S deficiency.
27
The objective of this study is to compare the prothrombotic tendency of patients with MINOCA with that of MI patients with obstructive CAD (MICAD), by testing for known congenital and acquired thrombophilia conditions, markers of coagulation activation, and global coagulation by the thrombin generation assay. Our primary objective is to compare overall thrombin generation potential using thrombin generation test between MINOCA and MICAD. Secondary objectives are to compare congenital thrombophilia states, acquired thrombophilia states, and coagulation markers between these two groups.
Methods
To achieve this objective, we employed a case-control study design recruiting age-and gender-matched patients with MIN-OCA and MICAD. Patients admitted for an acute MI at The Queen Elizabeth Hospital, Adelaide, Australia, were prospectively screened from May 2013 to March 2015 and were included if the following criteria were met: (1) fulfil the universal diagnostic criteria for an acute MI 4 based on troponin elevation with corroborative clinical criteria and (2) coronary angiography performed in the context of MI demonstrating MINOCA nonobstructive (<50% stenosis) coronaries or MICAD, obstructive (!50% stenosis) coronaries. Patients were excluded from this study if they were on anticoagulant treatment, diagnosed with Takotsubo cardiomyopathy, and identified with noncardiac or chronic causes of troponin elevation such as heart failure, pulmonary disease, and chronic kidney disease. Patients with confirmed MINOCA following coronary angiogram and sequential age-and gender-matched MICAD were consecutively approached and prospectively recruited into the study. All patients gave informed consent. The study was approved by the hospital human research ethics committee.
Blood sample was collected 4 weeks after the initial acute MI presentation, to avoid any influence from acutely administered drugs such as heparin or other anticoagulant agents, or activation of coagulation associated with the acute event.
A minimal stasis using a 21-G needle into plastic 3.5-mL Vacuette tubes (Greiner Bio-One, Austria) containing buffered sodium citrate (final concentration: 0.105 mol/L), serum, and EDTA was used. Citrate plasma samples were processed within an hour of blood collection by a single centrifugation for 15 minutes at 2,200 g (4,000 rpm), with the top two-thirds of the plasma then removed, and stored in aliquots at À70°C.
Thrombin generation was measured using calibrated automated thrombin generation assay (CT, Thrombinoscope BV, Maastricht, The Netherlands) in a Fluoroscan Ascent fluorometer (Thermolab systems OY, Helsinki, Finland) using PPP reagent (5pM tissue factor, 4uM phospholipids, Thrombinoscope) as previously described by Rodgers et al. 5 MIN-OCA and matched MICAD samples were always tested in the same run, to avoid any effects due to variation between assays. In addition, two aliquots of quality control plasma samples and a commercial lyophilized plasma sample (HemosIL Calibration Plasma; Instrumentation Laboratory, Bedford, Massachusetts, United States) were also tested in the same run in each assay for validation. Assays were repeated if the quality control results were not in the desired range. The effect of thrombomodulin (TM) on thrombin generation was tested by the addition of rabbit lung TM (lot 140711; Sekisui, Stamford, Connecticut, United States), which was added into the reaction mixture at a final concentration of 0.35 unit/mL (5.89 nM). Readings from the fluorometer were automatically recorded and calculated using dedicated software (Thrombinoscope) that displays thrombin generation curves (time vs. generated thrombin) and calculates endogenous thrombin potential (ETP), peak thrombin, velocity index, lag time, and time to peak.
Congenital Thrombophilia States
FVL and PGM were identified by primer extension genotype analysis using the Sequenom MassARRAY platform (Sequenom, San Diego, California, United States). The activities of antithrombin (AT, CV 4.7%) and protein C (PC, CV 2.8%) were assayed using a chromogenic substrate method, and free protein S antigen (PS, CV 4.7%) using latex immune-assay method on a STA-R analyser (Diagnostica Stago, France).
Acquired Thrombophilia States
Lupus anticoagulant (CV 4.8%) was measured by a diluted Russell viper venom time assay (STA-Staclot DRVVT Screen, Stago). Anticardiolipin antibodies (CV 3.5%) were detected by a quantitative enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN Medizinische Labordiagnostika AG, Germany) according to the manufacturer's instructions. Factor VIII coagulant activity (FVIII:C, CV 4.2%) was measured using a two-stage chromogenic assay (Biophen FVIII:C, Hyphen-Biophen, Neuville-sur-Oise, France), von Willebrand factor antigen (VWF: Ag, CV 15%) using latex immunoassay (STA-Liatest for VWF, Stago), and fibrinogen (CV 6%) using Clauss clotting method (STA-Fibrinogen, Stago) on a STA-R analyser (Diagnostica Stago).
Coagulation Marker
D-dimer was measured using an immune-turbidimetric method (STA-Liatest D-DI, Stago) on a STA-R analyser (Diagnostica Stago).
TH Open Vol. 2 No. 2/2018
Thrombosis Risk in MINOCA Pasupathy et al. e168
Baseline characteristics, thrombin generation test variables (includes ETP, peak thrombin, lag time, and time to peak), and thrombophilia screen results were described in MINOCA patients in comparison to MICAD patients. Mean with range or medians with 25th and 75th percentiles were reported for continuous variables, and frequencies for categorical variables. Continuous variables were compared using either unpaired t-test with equal standard deviation or Mann-Whitney U-test. Categorical variables were compared using Fisher's exact test. A p-value of <0.05 was considered significant in all comparisons. Statistical analysis was performed using Graph Pad Prism software package for MAC OS X, version 6.0 (San Diego, California, United States). 4, 144 .9]) respectively, although there was a trend for higher values for ETP, peak, and velocity in the MICAD group. Addition of TM did not yield any statistically significant differences between the two groups either (►Table 2).
Results

Between
Thrombophilia screening results are shown in ►Table 3. Neither mean levels of the congenital inhibitors of coagulation (AT, protein C, and protein S) nor the incidence of patients with abnormally low test results differed significantly between MINOCA and MICAD patients. The prevalence of patients with the FVL or PGM mutations was low in both the MINOCA and MICAD groups (0 vs. 4%, 8 vs. 4%) and did not significantly differ (p > 0.05). Antiphospholipid antibodies (lupus anticoagulant and anticardiolipin antibodies) were not found in any of the patients from both groups. Mean levels of F VIII:C, VWF:Ag, and fibrinogen were not significantly different between MINOCA and MICAD patients, and the incidence of patients with results above the normal range did not differ significantly. The proportion of patients with elevated D-dimer level (44 vs. 36%, p > 0.05) was similar in both groups, and mean levels did not differ significantly.
Discussion
Underlying thrombophilia resulting in an increased tendency to intravascular thrombosis have been postulated as one of the possible causes of MINOCA in previous studies and reviews. 3, 6 This study is the first of its kind to examine the thrombin generation in this patient group. It demonstrated similar thrombin generation activity in MINOCA patients to a matched MICAD population, along with no difference in the results of testing for recognized congenital or acquired thrombophilia states, and similar D-dimer results. presented only 1 patient with protein C or S deficiency in two studies with 73 and 78 MINOCA patients. The presence of FVL is the most common risk factor for venous thrombosis and has often been associated with clear as yet. Significant elevation of FVIII:C in both groups was noted in the present study; whether this elevation was associated with an acute phase response could not be clearly ruled out, and later testing may have been of benefit.
Elevated plasma fibrinogen levels, whatever their origin, may cause a hypercoagulative state that could influence the degree and duration of thrombus formation at the time of coronary injury. Previous reports suggest that fibrinogen is an independent risk factor for premature AMI. 26 The present study showed slightly raised levels of fibrinogen in both groups, which could be due to the MI or an underlying vascular disease than as a cause of MI. D-Dimer, an expression of on-going thrombus formation and lysis, is a marker of substantial incremental value for the early diagnosis of acute coronary syndromes. It adds independent information to the traditional assessment for acute MI. Although there are no previous studies comparing the elevated D-dimer in MINOCA with that in MICAD, because of the wide overlap between the groups, increased D-dimer values are of limited relevance above and beyond other risk factors. Nonetheless, it demonstrates increased fibrinolytic activity 4 weeks' post-MI in both groups.
Limitations
The results from this study should be interpreted in the context of several potential limitations. Thrombin generation assay does not measure the cell components of coagulation, thus giving a partial view of the hemostatic system. We also did not examine thrombin generation using a lower trigger concentration of tissue factor (1pM). The relatively small sample size may also explain the negative findings, particularly regarding the rarer inherited deficiency states. A sample size calculation for congenital thrombophilia states based on Dacosta et al's findings revealed that to test the proportion difference of 7.5 and 18.2%, at 80% power and 5% significance, 171 patients in each group would be required. It will also be beneficial to compare the MINOCA and MICAD cohort to age-and gender-matched healthy cohort in whom prior MI or CAD is not documented. In addition, the higher incidence of non-STEMI in the MINOCA group is also a limitation.
Conclusion
In summary, overall thrombin generation potential, congenital thrombophilia states, acquired thrombophilia states, and coagulation markers in this study were not different between MINOCA and MICAD patients, suggesting that despite the difference in coronary artery anatomy of the disease progression, acute MI patients generate thrombin in a similar manner in response to local stimuli. Although the role of an abnormal prothrombotic tendency is often hypothesized to be causative in the setting of MINOCA, whether testing for such an underlying condition helps in the clinical management of MINOCA is questionable. From our findings, the testing for hereditary thrombophilia would not alter the clinical management of patients; however, it could provide important mechanistic insights only in a minority of patients.
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